Amgen Refocuses Pipeline As Rocatinlimab Exit Reshapes Dermatology Outlook [Yahoo! Finance]
KIRIN HLDGS CO LTD S/ADR (KNBWY)
US:NASDAQ Investor Relations:
kirinholdings.co.jp/english/ir
Company Research
Source: Yahoo! Finance
Amgen (NasdaqGS:AMGN) has ended its collaboration with Kyowa Kirin on the atopic dermatitis drug rocatinlimab. The decision is tied to portfolio prioritization and returns full program control to Kyowa Kirin. The move signals a shift in Amgen's focus within its dermatology and autoimmune pipeline. For you as an investor, this development sits at the intersection of immunology, dermatology and large molecule drug development. These are areas where Amgen has been active across multiple indications. The end of the rocatinlimab partnership reshapes how its dermatology efforts fit alongside its broader immunology, oncology and cardiovascular businesses, at a time when competition in autoimmune therapies remains intense. Looking ahead, the key question is how Amgen reallocates R&D capital and internal resources now that rocatinlimab is off the table. You may want to watch for updates on its remaining immunology assets, any new business development moves in dermatology and whether m
Show less
Read more
Impact Snapshot
Event Time:
KNBWY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KNBWY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KNBWY alerts
High impacting KIRIN HLDGS CO LTD S/ADR news events
Weekly update
A roundup of the hottest topics
KNBWY
News
- Assessing Amgen (AMGN) Valuation After Ending Kyowa Kirin Rocatinlimab Collaboration [Yahoo! Finance]Yahoo! Finance
- Kyowa Kirin to regain control of rocatinlimab development, commercialization [Yahoo! Finance]Yahoo! Finance
- Is Kyowa Kirin (TSE:4151) Pricing Look Attractive After Recent Share Price Weakness [Yahoo! Finance]Yahoo! Finance
- Amgen ends collaboration agreement with Kyowa Kirin for eczema asset [Seeking Alpha]Seeking Alpha
- Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic DermatitisGlobeNewswire